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An Aspirin a Day . . .*
Carl L. Backer, MD†‡
Chicago, Illinois
The old adage, “an apple a day keeps the doctor away,”
when altered to “an aspirin a day keeps the doctor away”
appears to be especially appropriate for patients who have
had a Fontan operation. The group from the Hospital for
Sick Children has in this issue of the Journal reported a
secondary analysis of an important trial of thromboprophy-
laxis after the Fontan procedure (1). In this secondary
analysis the Toronto group further investigated the
unique and important data set accumulated in their
previous study, “A Multicenter, Randomized Trial Com-
paring Heparin/Warfarin and Acetylsalicylic Acid as
Primary Thromboprophylaxis for 2 Years After the Fon-
tan Procedure in Children” (2).
See page 346
Any surgeon who performs the Fontan procedure has
encountered at some point in his or her career a thrombotic
post-operative complication. These patients appear to be at
risk of thromboembolism for many reasons: a known
hypercoagulable state, the use of intracardiac prosthetic
materials, atrial arrhythmias, intracardiac shunting (fenes-
tration), low-flow states, and stasis in the venous pathways.
The original paper published by the Toronto group ran-
domized patients to receive either aspirin (5 mg/kg/day) or
warfarin with a target international normalized ratio of 2.0
to 3.0 (2). A total of 111 eligible patients were randomized
in a prospective fashion. The incidence of thrombosis was
essentially identical between the 2 groups and major bleed-
ing occurred in only 1 patient in each group. The conclusion
of this randomized prospective trial was that there was no
significant difference between aspirin therapy and warfarin
as primary thromboprophylaxis in the first 2 years following
the Fontan procedure. The thrombosis incidence was still
high at 19% in both groups, which the authors suggested
means there is still room for improvement in the care of
these patients.
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areas for improvement that might be brought to the
forefront from the original study group. This secondary
analysis of a unique and important dataset revealed the
following important factors. First, the hazard of throm-
bosis was noted to be highest immediately after the
Fontan procedure, but there was also a gradual increase in
risk during late follow-up. The higher incidence of
thromboembolism in the first several weeks and months
following the Fontan procedure has been previously
demonstrated and has some logical explanations. The
delayed hazard, however, seems somewhat counterintui-
tive as one would think that after several years there
would be less chance of thrombosis formation at suture
lines and along prosthetic pathways which presumably
would become covered with neointima over a period of
time. The inference here is that lifetime anticoagulation
of some sort is probably necessary.
The most striking and important new information,
though, appears to be the fact that patients who were on
a warfarin dose that was subtherapeutic actually had a
significantly increased incidence of thrombosis issues
compared with patients who were maintained on either
carefully controlled warfarin therapy or the aspirin ther-
apy. It is well known to clinicians that the difficulties of
managing warfarin therapy in children are not insignifi-
cant. Missing doses, changing diets, and intercurrent
illnesses all affect the international normalized ratio
levels. The ease of aspirin administration by contrast and
the attendant higher compliance presumably accounts for
the improved outcomes.
There were several other findings with the secondary
review regarding the factors associated with a higher risk of
thrombosis: 1) the diagnosis of pulmonary atresia with
intact ventricular septum; 2) pulmonary artery distortion; 3)
higher pre-operative unconjugated bilirubin; 4) the use of
central venous lines for10 days or until hospital discharge;
and 5) a lower FiO2 24 h after the procedure. Pulmonary
rtery distortion is understandable, as is prolonged central
ine use. The others are not necessarily intuitive.
Other surgeons have previously suggested that aspirin
herapy may be a better strategy after the Fontan proce-
ure than the use of warfarin. Marshall Jacobs published
study in 2002, “Fontan’s Operation: Is Aspirin Enough?
s Coumadin Too Much?” (3). He was actually quite
rescient in his analysis as many of the points demon-
trated by this secondary analysis were noted in his
eview. His conclusion was that “low dose aspirin can be
sed safely in young patients with Fontan connections. In
he intermediate follow-up the strategy of aspirin therapy
as effective in preventing thromboembolic complica-
ions. The routine use of more aggressive anticoagulation
uch as Coumadin may be unwarranted” (3). Those
onclusions from a very experienced Fontan surgeon were
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spective study!
It may be that improvements in surgical techniques (i.e., the
use of a bidirectional superior cavopulmonary anastomosis and
the extracardiac Fontan) will decrease the incidence of throm-
boembolic events. These operations are associated with more
laminar blood flow and less blind cul-de-sacs than the previ-
ously described atriopulmonary and lateral tunnel Fontan
operations. These operations avoid stasis in the venous path-
ways and may decrease atrial arrhythmias that are known to
contribute to thrombus formation. Other risk factors such as
the need for bilateral bidirectional cavopulmonary anastomosis
may not be amenable to modification.
I congratulate the Toronto group on enhancing our
understanding of the important issue of thrombotic com-
plications after the Fontan operation. Their ability to
organize and conduct a randomized trial of thrombopro-
phylaxis is a notable event in pediatric cardiac surgery. The
secondary analysis has improved our understanding of how
to care for and prevent thrombotic complications in this
unique patient population.An apple a day keeps the doctor away. In Fontan patients
an aspirin a day seems to keep the clots away.
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